EUVIMEDEUVIMED entdecken
Crossref

Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival

Wenbing Duan, Jinsong Jia, Jing Wang, Xiaohong Liu, Wenjing Yu, Xiaolu Zhu, Ting Zhao, Qian Jiang, Guorui Ruan, Xiaosu Zhao, Hongxia Shi, Yingjun Chang und 5 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06001-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Wenbing Duan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, Ch…. Hauptthemen laut MEDLINE: Nucleophosmin, DNA Methyltransferase 3A, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Peking University People's Hospital Research and Development Funds, The Grants from the Beijing Municipal Science and Technology Commission, Peking University Medicine Fund for world's leading discipline or discipline cluster development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Co-occurring mutations are frequently observed in acute myeloid leukemia (AML) with NPM1 mutation, and NPM1 measurable residual disease (MRD) is an effective prognostic biomarker. This retrospective study investigated the impact of gene co-mutations and NPM1 MRD on outcomes in these patients. Among 234 patients, 11.5% carried the rare type NPM1 mutation (NPM1RT). The median age was 49 years (IQR 36-58), with a median follow-up of 30.4 months (IQR 12.1-55.7). Nine genes were mutated in > 10%, with DNMT3A (53.8%) and FLT3-ITD (44.4%) being most prevalent. Univariable analysis in 137 patients showed FLT3-ITD, DNMT3A co-mutations, and MRD2 < 3 log reduction predicted poorer survival. FLT3-ITD and DNMT3A co-mutations correlated with the lowest event-free (EFS) and overall survival (OS) (3-year EFS 30.0%; 3-year OS 34.4%; both p < 0.001). FLT3-ITD alone did not worsen survival compared to patients without FLT3-ITD. Multivariable analysis identified DNMT3A co-mutation [EFS, HR = 1.9, p = 0.021; OS, HR = 2.2, p = 0.023] and MRD2 ≥ 3 log reduction (EFS, HR = 0.2; OS, HR = 0.1, both p < 0.001) as independent survival predictors. Patients with FLT3-ITD and DNMT3A co-mutations or a MRD2 < 3 log reduction were identified as high risk, but allogeneic hematopoietic stem cell transplantation (allo-HSCT) improved survival significantly compared to chemotherapy only (3-year EFS, 57.9% vs. 30.0%, p = 0.012; 3-year OS, 72.9% vs. 34.4%, p = 0.001). In AML patients with NPM1 mutation, the detrimental impact of FLT3-ITD mutation was exacerbated by DNMT3A co-mutation. Poor-risk younger patients identified by FLT3-ITD and DNMT3A co-mutations or MRD2 < 3 log reduction benefit from allo-HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NucleophosminDNA Methyltransferase 3Afms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteDNA (Cytosine-5-)-MethyltransferasesNeoplasm, ResidualMutationNuclear ProteinsHumansMiddle AgedMaleFemaleAdultRetrospective StudiesPrognosisSurvival RateFollow-Up StudiesHematopoietic Stem Cell TransplantationDisease-Free Survival

Stichwörter der Autor:innen

FLT3-ITD and DNMT3A co-mutationNPM1 mutationMeasurable residual disease

Substanzen

NucleophosminNPM1 protein, humanDNA Methyltransferase 3ADNMT3A protein, humanfms-Like Tyrosine Kinase 3DNA (Cytosine-5-)-MethyltransferasesFLT3 protein, humanNuclear Proteins

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China. huangxiaojun@bjmu.edu.cn.
  • Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China. huangxiaojun@bjmu.edu.cn.
  • Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China. huangxiaojun@bjmu.edu.cn.
  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing, China. 2516735116@qq.com.

Förderung

  • Peking University People's Hospital Research and Development Funds
  • The Grants from the Beijing Municipal Science and Technology Commission
  • Peking University Medicine Fund for world's leading discipline or discipline cluster development
  • Peking University People’s Hospital Research and Development Funds

Zitieren

APA

Duan, W., Jia, J., Wang, J., Liu, X., Yu, W., Zhu, X., Zhao, T., Jiang, Q., Ruan, G., Zhao, X., Shi, H., Chang, Y., Wang, Y., Xu, L., Zhang, X., Huang, X., & Jiang, H. (2024). Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival. Annals of Hematology. https://doi.org/10.1007/s00277-024-06001-6

Vancouver

Duan W, Jia J, Wang J, Liu X, Yu W, Zhu X, et al. Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival. Annals of Hematology. 2024. doi:10.1007/s00277-024-06001-6

BibTeX
@article{Duan2024,
  author = {Duan, Wenbing and Jia, Jinsong and Wang, Jing and Liu, Xiaohong and Yu, Wenjing and Zhu, Xiaolu and Zhao, Ting and Jiang, Qian and Ruan, Guorui and Zhao, Xiaosu and Shi, Hongxia and Chang, Yingjun and Wang, Yu and Xu, Lanping and Zhang, Xiaohui and Huang, Xiaojun and Jiang, Hao},
  title = {Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06001-6}
}
Kostenlos starten →